v3.25.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 25,030 $ 25,841
Short-term investments 17,466 25,884
Restricted cash 146 146
Accounts receivable 1,482 34,108
Inventories 10,655 9,706
Other current assets 10,115 6,184
Total current assets 64,894 101,869
Property and equipment, net 1,294 3,856
Operating lease assets 39,807 54,935
Other assets 3,103 4,844
Total assets 109,098 165,504
Current liabilities:    
Accounts payable 4,367 3,684
Accrued compensation 6,589 11,519
Accrued research and development expenses 7,984 17,364
Deferred revenue 95,092 77,833
Other current liabilities 20,542 31,826
Total current liabilities 134,574 142,226
Deferred revenue - long-term 0 37,562
Operating lease liabilities - long-term 29,914 45,693
Liability related to the sale of future revenues - long-term 38,624 34,623
Other long-term liabilities 3,269 4,631
Total liabilities 206,381 264,735
Commitments and contingencies (Note 9)
Stockholders' equity (deficit):    
Common stock-$0.0001 par value, 500,000 shares authorized as of December 31, 2024 and 2023, respectively; 10,741 and 4,258 shares issued and outstanding as of December 31, 2024 and 2023, respectively 1 0
Additional paid-in capital 1,957,261 1,870,123
Accumulated other comprehensive (loss) income 8 (204)
Accumulated deficit (2,054,553) (1,969,150)
Total stockholders' equity (deficit) (97,283) (99,231)
Total liabilities and stockholders' equity (deficit) $ 109,098 $ 165,504

Source

10-K
HTML PDF
XBRL
ZIP